1800-272-662
Shopping Cart 0
countryflagAU
Login

Opthea Ltd

Healthcare US OPT

NoneUSD
-(-%)

Last update at 2025-04-17T14:14:17.459917Z

Day Range

--
LowHigh

52 Week Range

1.604.40
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap269.99M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-164.93389M
  • Revenue TTM0.39M
  • Revenue Per Share TTM0.008
  • Gross Profit TTM 0.22M
  • Diluted EPS TTM-2.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -148.44744M -99.11666M -50.28334M -17.22088M -24.89497M
Minority interest - - - - -
Net income -142.52108M -92.81737M -45.34450M -11.35760M -14.64413M
Selling general administrative 27.84M 17.83M 13.72M 4.00M 3.07M
Selling and marketing expenses - - - - 0.29M
Gross profit 0.11M 0.09M 0.07M - -
Reconciled depreciation 0.10M 0.08M 0.11M 0.14M 0.03M
Ebit -146.79830M -93.72380M -28.62855M -17.20638M -25.98888M
Ebitda -146.69707M -93.64542M -28.52189M -17.10742M -25.96570M
Depreciation and amortization 0.10M 0.08M 0.11M 0.10M 0.02M
Non operating income net other - - - - -
Operating income -146.79830M -93.72380M -28.62855M -17.20638M -25.98888M
Other operating expenses 150.13M 96.63M 39.71M 17.48M 25.73M
Interest expense 13.46M 0.24M 21.65M 0.01M 1.09M
Tax provision -5.92635M -6.29929M -4.93885M -8.53312M -14.63697M
Interest income 3.23M 0.24M 0.37M 0.72M 0.76M
Net interest income -10.23466M 0.24M 0.37M 0.72M 0.76M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.92635M -6.29929M -4.93885M -5.86328M -10.25084M
Total revenue 0.11M 0.09M 0.07M - -
Total operating expenses 150.13M 96.63M 39.71M 17.48M 25.73M
Cost of revenue - - - - -
Total other income expense net 11.81M -5.39286M -21.65479M -0.01449M 1.09M
Discontinued operations - - - - -
Net income from continuing ops -142.52108M -92.81737M -45.34450M -16.52928M -20.91006M
Net income applicable to common shares -142.52108M -92.81737M -45.34450M -16.52928M -20.91006M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 98.64M 60.05M 138.41M 49.40M 26.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 8.72M 14.39M 6.19M 10.55M
Total liab 104.40M 12.07M 3.12M 4.86M 4.58M
Total stockholder equity -5.75855M 47.98M 135.29M 44.53M 21.79M
Deferred long term liab - - - - -
Other current liab 0.75M 0.64M 0.58M 0.16M 0.43M
Common stock 320.88M 235.28M 234.15M 111.38M 79.15M
Capital stock 320.88M 235.28M 234.15M 111.38M 79.15M
Retained earnings -359.36781M -216.94135M -124.12398M -70.49118M -60.27121M
Other liab 0.00763M 0.03M 0.02M 0.04M 0.02M
Good will - - - - -
Other assets 0.05M 0.11M 0.17M - 0.00000M
Cash 89.19M 44.63M 118.19M 42.62M 15.08M
Cash and equivalents - - - - -
Total current liabilities 18.65M 12.04M 3.11M 4.75M 4.56M
Current deferred revenue - - - 0.48M -
Net debt -89.00700M -44.63129M -118.08021M -42.43330M -15.08174M
Short term debt 0.10M - 0.11M 0.10M -
Short long term debt - - - - -
Short long term debt total 0.18M - 0.11M 0.18M -
Other stockholder equity 32.73M 47977.14M 25.26M 0.00000M 0.00000M
Property plant equipment 0.20M 0.03M 0.12M 0.28M 0.05M
Total current assets 98.39M 59.91M 138.12M 49.00M 25.84M
Long term investments - - 0.00000M 0.29M 0.71M
Net tangible assets -5.85318M 47.98M 135.29M 64.81M 31.12M
Short term investments - - - - -
Net receivables 6.56M 6.56M 5.54M 0.20M 0.21M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 17.80M 11.40M 2.42M 4.01M 4.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 32.73M 29.64M 25.26M 3.64M 2.91M
Additional paid in capital - - - - -
Common stock total equity - - 234.15M 162.10M 113.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.05M 0.11M 0.17M 0.00000M -
Deferred long term asset charges - - - - -
Non current assets total 0.26M 0.14M 0.29M 0.39M 0.54M
Capital lease obligations 0.18M 0.00000M 0.11M 0.27M -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.02195M -0.01691M 0.67M 0.48M 0.32M
Change to liabilities 7.30M 8.51M -1.55244M -0.05691M -1.42798M
Total cashflows from investing activities -0.02195M -0.01691M 0.66M 0.48M 0.32M
Net borrowings 84.43M -0.08558M -0.08737M -0.10019M -0.10019M
Total cash from financing activities 167.29M 0.17M 116.94M 33.66M 8.85M
Change to operating activities 6.28M 5.85M -14.19104M 0.06M -0.06685M
Net income -142.52108M -92.81737M -45.34450M -11.35760M -14.64413M
Change in cash 44.56M -73.56188M 75.54M 27.82M -7.68644M
Begin period cash flow 44.63M 118.19M 42.65M 14.80M 22.77M
End period cash flow 89.19M 44.63M 118.19M 42.62M 15.08M
Total cash from operating activities -120.60838M -71.33495M -45.54617M -6.03447M -16.93781M
Issuance of capital stock 81.82M 0.00000M 105.48M 33.72M 8.85M
Depreciation 0.10M 0.08M 0.11M 0.14M 0.03M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.38M 0.31M -0.36971M 0.01M 0.10M
Sale purchase of stock - - - - -
Other cashflows from financing activities 85.54M 0.26M 11.55M -0.06884M 0.22M
Change to netincome 7.86M 6.74M 15.80M 7.58M -1.91131M
Capital expenditures 0.02M 0.02M 0.01M 0.00497M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 13.95M 14.66M -16.11319M - -
Stock based compensation 5.83M 5.25M 3.90M - -
Other non cash items 7.95M 7.79M 16.85M 11.21M 14.61M
Free cash flow -120.63033M -71.35186M -45.55887M -6.03944M -16.95046M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OPT
Opthea Ltd		 - -% - - 6.73 806.35 4.31 1325.04 -1.0348
NVO
Novo Nordisk A/S		 -0.06 0.16% 37.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.315 0.82% 38.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -8.79 1.84% 469.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.84 0.11% 745.77 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 "VEGFR-3", currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Opthea Ltd

650 Chapel Street, South Yarra, VIC, Australia, 3141

Key Executives

Name Title Year Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. MD, CEO & Exec. Director 1974
Ms. Judith J. Robertson B.A., M.B.A. Chief Commercial Officer 1960
Dr. Joel Naor M.D., MBA, MSc Chief Medical Officer NA
Ms. Karen Adams CPA VP of Fin. & Company Sec. 1971
Mr. Timothy E. Morris CPA, CPA Chief Financial Officer 1961
Ms. Annie Lee Fin. & Operations Mang. NA
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Devel. 1964
Mr. Bruno Gagnon BPHARM, M.Sc. Sr. VP of Global Clinical Operations NA
Dr. Ian Leitch Director of Clinical Research 1963
Dr. James Goding Independent Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.